		ign (+) inside t	/				MM Sections In	domade Office:	e through 10/31/2 U.S. DEPARTN it contains a valk	2002. (	ECOM	1-0031
			\ <u>A</u>	4	in the same of	LLED		nplete if Kı		TECH		
				(B)	REMARKORINA INT	Application Nur	nber	10/081.119		Ä	e	
ľ	INFOR	NOITAM	DISCL	.Ogů	REMAN	Filing Date		February 2	1, 2002	m	_ <u></u>	
	STATI	EMENT B	Y APP	LICA	INT	First Named Inv	ventor	Reinhard.	et al.	$\preceq$		
ľ						Group Art Unit		1645		Щ		四
	(use_	as many shee	ets as nec	essar	y)	Examiner Name		Unassigne	d	70	ಲ್	
Sheet		1		of	1	Attomey Docket	Number	2300-1693	2	9	20	
		·		<del></del>		<u> </u>		<del>*</del>		0	02	
					115 5	ATENT DOCUM	MENTS			धु		
Examin er Initials'	Cite No.1	U.S. Pat	lent Docun Kin (if know	d Code	Name of Par	tentee or Applicant d Documents	Date of Public of Cited Docu MM-DD-YY	ment	Pages, colu Where R Passages o Figures	Relevani or Relev	t /ant	
			-							سحميم		
											- <del></del>	
					FORFIG	N PATENT DOC	UMENTS					
Examiner	Cite	Foreign	n Patent D	осите	nts	Name of Patentee or		f Publication	Pages, Colu Where F			

Applicant of Cited Documents

Where Relevant

Passages or Relevant

Figures Appear

of Cited Document

MM-DD-YYYY

Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Initials*		item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), oublisher, city and/or country where published.	T
tν		CAHILL, et al. "Characterization of MAD2B and other mitotic spindle checkpoint genes", Genomics, (1999) Vol. 58(2): 181-187.	
		GENBANK Accession No. M86699	
		HANAHAN, et al. "The hallmarks of cancer", Cell, (2000) Vol. 100: 57-70.	_
		HARUKI, et al. "Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in human lung cancers", Cancer Letters, (2001) Vol. 162: 201-205.	L
		HOGG, et al. "Cell cycle dependent regulation of the protein kinase TTK", Oncogene, (1994) Vol. 9: 89-96.	
		MILLS, et al. "Expression of TTK, a novel human protein kinase, is associated with cell proliferation", J. Biol. Chem., (1992)-Vol. 267: 16000-16006.	
		MIMORI, et al. Oncol. Rep., (2001) Vol. 8: 39-42.	
		OLESEN, et al. "Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3, and TTK in human bladder cancer, screening for mutations and loss of heterozygotsity", Carcinogenesis, (2001) Vol. 22(5): 813-815.	
		SAFFERY, et al. "Components of the human spindle checkpoint control mechanism localize specifically to the active centromere on dicentric chromosomes", <i>Hum. Genet.</i> , (2000) Vol. 107; 376-384.	
		SCHMANDT, et al. "IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression", <i>J. Immunol.</i> , (1994) Vol. 152: 96-105.	
V		TOMIZAWA, et al. "Tau-tubulin kinase phosphorylates tau at Ser-208 and Ser-210, sites found in paired helical filament-tau", FEBS, (2001) Vol. 492: 221-227.	

Examine Signatur	aan Wirk	my 70	Date Considered	10/20/04	

Office

No.1

Initials'

Number<sup>4</sup>

Kind Code<sup>5</sup>

(if known)

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (SB)

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

, SEP 182	C 28 oder	e a plus sign (+) inside this box → the Paperwork Reduction Act of		no persons are	PTO/SB/08A (08-00)  Approved for use through 10/31/2002. OMB 0651-0031  U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE required to respond to a collection of information unless it contains a valid OMB control number.					
E.	Stitute	for form 1449A/PTO  UPPLEMENTAL INFO			С	omplete if Known	BECEIVED			
TRADEM					Application Number	10/081,119	RECEIVED			
	S	UPPLEMENTAL INFO	RMA	ATION	Filing Date	February 21, 2002				
•	Į	DISCLOSURE			First Named Inventor	Reinhard, et al.				
	STATEMENT BY APPLICANT				Group Art Unit	1645	SEP 2 0 20 D2			
	4	OTATION OTTO			Examiner Name	Unassigned				
•		(use as many sheets as nec	essa	rv)			TEAL OF NEED 4000000			
	Sheet	1	of	1	Attorney Docket Number	2300-16932	TECH CENTER 16(00/290			

				U.S. PATENT DOCUM	MENTS	
Examin er Initials'	Cite No. <sup>1</sup>	U.S. Patent Docume  Number Kind ( (if known)	Code <sup>2</sup>	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		***				

			F	OREIGN PATENT DOCUME	NTS		
Examiner	Cite	Foreign Patent		Name of Patentee or	Date of Publication	Pages, Columns, Lines, Where Relevant	
Initials'	No.1	Office <sup>3</sup> Number	Kind Code <sup>5</sup> (if known)	Applicant of Cited Documents	of Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sub>e</sub>
TV		WO 00/	56756	Bancroft et al.	09-28-2000		

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Dubl	From	SCHMANDT, et al. "IL-2-induced expression of TTK, a-serine, threonine, tyrosine kinase, correlates with cell cycle progression", J. Immunol., (1994) Vol. 152:96-105.	
] 55 II	12		

7/10/02

Examiner Signature

Date Considered 10 20 04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. (SB)